Where are we now with changing cholesterol levels to reduce cardiovascular disease risk? Keith Fox (British Cardiovascular Society president) asks Rory Collins (professor of Medicine and Epidemiology and co-director of the Clinical Trial Service, Nuffield Department of Clinical Medicine, University of Oxford).

Professor Collins talks about the evidence behind altering high- and low-density lipoproteins, why the issue of myopathy has been overstated, and our best treatment options now and for the future.

See also:

Webcasts from all the sessions at the British Cardiovascular Society Conference 2012 http://bit.ly/ZMGmUE